SillaJen

SillaJen, Inc. has its head office at 106 Cheonggyecheon-ro in Seoul, a research centre in Gwanggyo, a pharmaceutical division in Suwon and an office in San Diego, according to its website, which describes it as developing oncolytic immunotherapeutics. Its pipeline page lists BAL0891, a dual TTK and PLK1 inhibitor (the page cites a 2022 Basilea presentation as a source), alongside oncolytic vaccinia virus programmes. The company says BAL0891 is in a phase 1 dose-escalation trial in relapsed or refractory solid tumours (NCT05768932, which ClinicalTrials.gov lists as also enrolling relapsed or refractory acute myeloid leukaemia). On 24 August 2026 the FDA granted orphan drug designation for the treatment of acute myeloid leukaemia to a product the database describes as a small-molecule mitotic checkpoint inhibitor with dual inhibition of TTK and PLK1; the company's website headlines the designation as one for BAL0891.